Incidental pulmonary emboli are associated with a very high probability of progressive malignant disease on staging CT scans
Tóm tắt
The link between malignancy and venous thromboembolism (VTE) is well established; the risk has been shown to be higher in certain tumour types and in patients receiving platinum-based chemotherapy regimens. ‘Active’ cancer is often quoted as being a particular risk factor for VTE, but the definition varies widely and the supporting evidence is weak. This study was conceived to establish whether incidental pulmonary emboli are associated with an increased likelihood of progressive disease on a staging computed tomography (CT) scan. All CT scans containing incidental PEs over the course of a year in a large specialist cancer hospital were examined (n = 306). An age-matched control group was assembled. Multivariate logistic regression analysis was performed to establish the relationship of several independent variables, including progressive disease, with the dependent variable of the presence or absence of incidental pulmonary emboli. Progressive disease was present in 144 of 306 (47.1%) of the patients in the PE group but only 63 of 306 (20.6%) of the control group patients. Progressive disease on the staging CT scan was found to have an odds ratio for incidental PE of 3.46, with a 95% CI of 2.38–5.01. Receiving platinum-based chemotherapy resulted in an odds ratio of 3.89 (2.41–6.28) for PE. Receiving non-platinum-based systemic anti-cancer therapy (SACT) resulted in an odds ratio for PE of 1.71 (1.16–2.50). The detection of an incidental PE on a staging CT scan is associated with a very high risk of progressive malignant disease.
Từ khóa
Tài liệu tham khảo
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22.
Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer—a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13.
Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau’s syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204–8.
Reynolds MW, Shibata A, Zhao S, Jones N, Fahrbach K, Tim GL. Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin. 2008;24(2):497–505.
Stein PD, Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin. 2011;27(4):907–32.
Bach AG, Schmoll H-J, Beckel C, Behrmann C, Spielmann RP, Wienke A, et al. Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. Acta Radiol. 2014;55(1):45–53.
Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev. 2009;23(5):225–9.
Schmaier AA, Ambesh P, Campia U. Venous thromboembolism and cancer. Curr Cardiol Rep. 2018;20(10):89.
Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol. 2009;22(1):9–23.
Abdol Razak N, Jones G, Bhandari M, Berndt M, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers. 2018;10(10):380.
Lee Y-G, Lee E, Kim I, Lee K-W, Kim TM, Lee S-H, et al. Cisplatin-based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer. Cancer Res Treat Off J Korean Cancer Assoc. 2015;47(4):670.
Zahir MN, Shaikh Q, Shabbir-Moosajee M, Jabbar AA. Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy—a cohort study. BMC Cancer. 2017;17(1):57.
Abdel-Razeq H, Mansour A, Abdulelah H, Al-Shwayat A, Makoseh M, Ibrahim M, et al. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Thromb J. 2018;16(1):2.
Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep. 2010;23(1):247–53.
Dou F, Li H, Zhu M, Liang L, Zhang Y, Yi J, et al. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer. Respir Res. 2018;19(1):88.
Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019;30(6):897–907.
Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A validated risk score for venous thromboembolism is predictive of cancer progression and mortality. Oncologist. 2016;21(7):861–7.
Ma L, Wen Z. Risk factors and prognosis of pulmonary embolism in patients with lung cancer. Medicine (Baltimore). 2017;96(16): e6638.
Kilburn A, Iddles SI, Carrington BM. Radiographer screening for incidental pulmonary emboli on routine contrast-enhanced computerised tomography scans at a cancer centre. Clin Radiol. 2018;73(2):219.e1–7.
Caraiani C, Pop A, Calin A, Ciobanu L, Militaru C, Berghe A, et al. Incidental findings during follow-up scans in oncological patients. Med Pharm Rep. 2018;91(3):293–9.
Myat Moe MM, Redla S. Incidental pulmonary embolism in oncology patients with current macroscopic malignancy: incidence in different tumour type and impact of delayed treatment on survival outcome. Br J Radiol. 2018;91(1088):20170806.
Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol. 2010;5(6):798–803.
Donadini MP, Dentali F, Squizzato A, Guasti L, Ageno W. Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. Intern Emerg Med. 2014;9(4):375–84.
Thaker D, Douglas E, Blazak J, Xu W, Hughes B, Burge M, et al. An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients. Asia-Pacific J Clin Oncol. 2017;13(3):243–8.
Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401–10.
Biedka M, Ziółkowska E, Windorbska W. Acute pulmonary embolus in the course of cancer. Contemp Oncol. 2012;16(5):388.
Furie B, Furie BC. Cancer-associated thrombosis. Blood Cells Mol Dis. 2006;36(2):177–81.
Rybstein MD, DeSancho MT. Hypercoagulable states and thrombophilias: risks relating to recurrent venous thromboembolism. In Thieme Medical Publishers; 2018. p. 99–104.
Caul S, Broggio J. Cancer registration statistics, England - Office for National Statistics [Internet]. Office for National Statistics. 2019 [cited 2019 Jun 6]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2017#the-three-most-common-cancers-vary-by-sex-and-age-group